Proton pump inhibitors in FAERS: 876,621 adverse-event reports by the numbers

The FDA Adverse Event Reporting System (FAERS) holds 876,621 individual safety reports that name at least one of the six proton pump inhibitors (PPIs) still marketed in the United States — omeprazole, pantoprazole, esomeprazole, lansoprazole, dexlansoprazole, and rabeprazole — in any role, filed between 2004, when the modern openFDA FAERS record begins, and early 2026. Omeprazole leads the class with 284,176 reports (32.4 percent of the class total), a share that reflects its status as both the highest-volume prescription PPI and the leading over-the-counter (OTC) product, followed by pantoprazole (245,570), esomeprazole (220,164), and lansoprazole (158,003); dexlansoprazole and rabeprazole together account for less than 8 percent. Of the class-level reports, 660,709 — 75.4 percent — carry an FDA seriousness flag, and 78,091 (8.9 percent) record a fatal outcome. The class skews female — 474,352 reports in female patients against 324,473 in male patients (59.4 percent female) — consistent with the higher prevalence of GERD and the longer average PPI exposure in women. The single dominant label-relevant signal is renal: 70,758 reports in the acute-kidney-injury and interstitial-nephritis family, the largest single adverse-event family in the class and the backbone of the 2020 FDA relabeling from "acute interstitial nephritis" to "acute tubulointerstitial nephritis." The chronic-use safety debate that has surrounded the class since 2010 is visible in the rest of the footprint: 28,250 fracture and bone reports, 23,302 pneumonia reports, 18,655 vitamin-B12-deficiency and anaemia reports, 12,467 hypomagnesaemia and electrolyte reports, and 2,189 subacute-cutaneous-lupus reports.

This article is a class-level descriptive read of PPI reporting in FAERS, written for pharmacovigilance, medical-affairs, gastroenterology market-access, and formulary teams who encounter PPI safety numbers in labeling reviews, duration-of-therapy policy, and the chronic-use safety debate. Every figure here is computed from the public openFDA FAERS extract (20,328,575 total reports, export dated 2026-06-08). It is not a disproportionality signal analysis, it is not a safety claim, and it is not incidence data. FAERS is a spontaneous-reporting system: it captures what was reported, never what was caused, it has no exposure denominator, and PPI reporting is dominated by a vast, mostly older, mostly outpatient chronic-use population in which fractures, pneumonia, kidney injury, and death are common regardless of attribution. The exposure context is essential: tens of millions of US patients take a PPI in any given year, the great majority at OTC doses for short courses but a large minority on prescription-strength, multi-year therapy, so the reporting volume here is a vanishingly small slice of real-world exposure. Those caveats shape every number below. For the class-wide FAERS methodology and the database aggregate picture, see the companion analysis of 20 million FAERS reports; for the other class cuts, see atypical antipsychotics, antiepileptic drugs, statins, GLP-1 receptor agonists, SGLT2 inhibitors, JAK inhibitors, DOACs, and checkpoint inhibitors in FAERS. This article stays on the six marketed PPIs.

Methodology, in one paragraph

A report is counted for an agent when the generic or brand name appears as an exact drug-field token in that report — as a suspect, concomitant, or interacting drug — using an exact-token match across the drug_substances, drug_generics, and drug_brands fields (a |-delimited token match, so that the same number is not double-attributed across the class). Because a single report can name several PPIs (switching between agents during chronic therapy is common), the per-agent totals sum to more than the 876,621 class-level (union, deduplicated) reports. A "serious" report is any report the FDA coded as serious. A report counts toward death when either the seriousness field carries a death flag or the outcome field carries a Fatal outcome. Reactions are coded to MedDRA Preferred Terms; reaction counts are case-normalized. The adverse-event families aggregate related Preferred Terms (for example, "acute kidney injury / interstitial nephritis" combines acute kidney injury, interstitial nephritis, renal failure, chronic kidney disease, and renal impairment; "hypomagnesaemia / electrolyte" combines hypomagnesaemia, decreased blood magnesium, hypocalcaemia, decreased blood calcium, and hypokalaemia; "subacute cutaneous lupus" combines subacute cutaneous lupus erythematosus, systemic lupus erythematosus, and lupus-like syndrome), and a report contributes once to a family if any term in the family appears. The "any role" counts reported here are intentionally inclusive, so they will exceed suspect-only or differently normalized counts cited elsewhere for the same agent.

The reporting-volume picture, by drug

Three patterns matter for access and medical-affairs teams. First, reporting volume tracks market penetration and OTC availability, not intrinsic risk: omeprazole leads because Prilosec OTC is the highest-volume PPI in the country, and pantoprazole and esomeprazole follow because Protonix (a long-time preferred hospital and formulary agent) and Nexium (the one-time highest-selling prescription drug globally) carried the largest prescription-exposed denominators. Second, the serious-share band runs from 70.7 percent for esomeprazole to 86.6 percent for lansoprazole, a narrow range that reflects a homogeneous class taken by a similar older, multi-morbid, chronic-use population — unlike the psychiatric or anticonvulsant classes, the PPIs do not have large agent-specific population differences, so the serious shares cluster. Third, the per-drug death-flag percentages cluster tightly between 8.1 and 11.8 percent and move with population age and acuity (rabeprazole's 11.8 percent is a smaller-denominator artifact at 30,403 reports), not with a clean drug-safety ranking; PPIs are pharmacologically near-equivalent and the safety labeling is class-wide, so no single agent carries a distinct death-flag differential that would support formulary distinction on safety grounds.

The class-level outcome profile

A report can carry more than one outcome, so these shares sum to more than 100 percent. The Fatal outcome count (57,545) sits below the death-flag measure (78,091) because not every death-flagged report carries a resolved Fatal outcome field. As with every FAERS outcome table, none of these percentages are incidence — the denominator is reports, not exposed patients. Given that tens of millions of patients take PPIs in any given year, the reporting volume here is an exceptionally small, skewed slice of real-world exposure, and the high "not recovered" and "fatal" shares reflect an older, multi-morbid reporting population in which chronic kidney disease, fractures, and pneumonia resolve slowly or not at all.

The renal, fracture, and chronic-use footprint

Stripping out the non-specific terms (diarrhoea, nausea, abdominal pain, dyspnoea, fatigue) that dominate the raw reaction list for any high-volume gastrointestinal class, the label-relevant adverse-event families that define the PPI safety profile leave a clear footprint:

The footprint maps directly onto the 2010–2020 sequence of FDA labeling actions. The renal signal is the largest single family in the class and the basis for the most consequential recent label action: in May 2020, an FDA review team recommended revising the prescription PPI class warning from "acute interstitial nephritis" to "acute tubulointerstitial nephritis" to capture both the acute and chronic renal phases, citing increased FAERS reporting of adverse renal events and a small study of biopsy-confirmed PPI-associated kidney injury. Acute interstitial nephritis has been a class warning in PPI labeling for over a decade, and the observational literature has reported a roughly 1.5- to 2-fold association between PPI use and incident chronic kidney disease and acute kidney injury — associations the FDA noted are limited by confounding and residual indication bias but are the basis for the renal reporting volume here. The fracture family (28,250 reports) traces to the May 25, 2010 FDA safety communication on hip, wrist, and spine fracture risk with high-dose or long-term (more than one year) PPI use; the hypomagnesaemia family (12,467) traces to the March 2, 2011 communication on low serum magnesium with use beyond one year (74 omeprazole cases were identified in FAERS at the time); the Clostridioides difficile family (2,248) traces to the February 8, 2012 communication on C. difficile-associated diarrhea; and the subacute-cutaneous-lupus family (2,189) traces to the cutaneous and systemic lupus erythematosus warning added to PPI labels in 2016–2017, under which the majority of PPI-induced cases were subacute cutaneous lupus erythematosus (SCLE) occurring weeks to years after continuous therapy. The vitamin-B12 family (18,655) reflects the in-label warning that daily long-term use (beyond roughly three years) may lead to cyanocobalamin malabsorption. The descriptive counts here are the reporting backdrop to that labeling sequence; the labels themselves rest on epidemiological and pharmacological evidence, not on inference from the spontaneous counts. Two further signals dominate the competitor and observational literature on long-term PPI use and deserve explicit framing even though they are not aggregated as discrete families in the table above. The first is chronic kidney disease: a 2016 JAMA Internal Medicine cohort (Lazarus et al.) reported an association between PPI use and incident chronic kidney disease, building on the acute-kidney-injury and interstitial-nephritis evidence that already anchors the renal family here — the mechanism is held to be an idiosyncratic interstitial-nephritis reaction that, in some patients, progresses to chronic disease. The second is dementia and cognitive decline: a series of observational analyses — the 2016 JAMA Neurology Qvist/Thyrian German study, UK Biobank and FinnGen analyses, a 2023 University of Minnesota Neurology study, and a December 2024 German Center for Neurodegenerative Diseases report linking three or more years of regular PPI use to impairments in cognitive and working memory and to white-matter disruption — have reported associations between long-term PPI use and dementia, though causation remains unproven and confounding by indication is substantial. Neither signal is the subject of an FDA boxed warning or a discrete FDA Drug Safety Communication, and neither appears as a family in the FAERS counts reported here; they are included for completeness because any market-access or pharmacovigilance review of the class will encounter them, and the cognitive signal in particular is the most-debated emerging PPI safety question.

The 2010–2020 FDA safety-communication sequence

The PPIs are the only class in this series whose entire contemporary safety profile was built through a decade-long sequence of post-marketing FDA communications and label revisions rather than through a single boxed warning or REMS. The sequence runs: the May 25, 2010 Drug Safety Communication on fracture risk with high-dose, long-term use (concluding that OTC-dose, short-course use did not warrant an OTC label change); the March 2, 2011 communication on hypomagnesemia with use beyond one year; the February 8, 2012 communication on Clostridium difficile-associated diarrhea; the class-wide addition of cutaneous and systemic lupus erythematosus warnings in 2016–2017; the long-standing acute-interstitial-nephritis warning; and the May 2020 recommendation to broaden the renal warning to "acute tubulointerstitial nephritis." The 876,621 class reports are the descriptive echo of that decade of regulatory attention, and the 2012 reporting spike in the trajectory table below (47,060 reports, up from 33,450 in 2011) coincides with the 2010–2012 communication sequence, which generated substantial prescriber and consumer reporting. The cumulative regulatory consequence is the now-standard label counsel to use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated — language that drives duration-of-therapy policy across commercial and Medicaid formularies.

The reporting trajectory, by year

The trajectory tracks the class's reporting ecosystem and the chronic-use safety debate, not a safety trend. The 2010–2012 step-up (from ~19,000 to ~47,000) coincides with the fracture, magnesium, and C. difficile FDA safety communications, which generated both prescriber attention and consumer-reporting volume; the 2015–2019 climb to a ~77,000-report peak tracks the broadening of the chronic-use safety debate (kidney disease, dementia, all-cause mortality associations in the observational literature) and rising long-term prescription PPI volume; and the post-2019 decline to a ~46,000-report steady state reflects both reporting normalization and the gradual implementation of deprescribing and duration-limit initiatives. The 2026 figure (10,116) is a partial year through the extract cut-off. The pre-2004 counts are negligible because the modern openFDA FAERS record begins in late 2003.

What this means for pharmacovigilance, medical-affairs, and access teams

• For pharmacovigilance teams, the class's 75.4 percent serious share and 8.9 percent death-flag rate are population effects, not signal. Read serious and death proportions against a vast, older, multi-morbid, chronic-use baseline in which fractures, pneumonia, kidney disease, and death are common; the signal that matters is the renal (acute kidney injury and interstitial nephritis) family, the largest in the class, alongside the disproportionality-documented fracture, magnesium, B12, and SCLE families.
• For medical-affairs and label teams, the renal signal is the durable pressure point. The 2020 broadening of the warning to "acute tubulointerstitial nephritis" and the continued FAERS renal reporting volume mean that any PPI label or risk-management review, and any new acid-suppression agent (including the potassium-competitive acid blockers), will be evaluated against this renal benchmark.
• For gastroenterology market-access and formulary teams, the "lowest dose, shortest duration" label counsel is embedded in duration-of-therapy, step-therapy, and quantity-limit policy. Commercial and Medicaid formularies routinely cap long-term PPI use, require step therapy from OTC to prescription strength, and flag chronic PPI prescribing for review — all driven by the 2010–2020 labeling sequence, not by these counts.
• For generic and OTC lifecycle teams, the OTC-versus-prescription distinction is load-bearing. The FDA concluded that OTC-dose, short-course PPI use does not carry the fracture or magnesium signal, which is why the warnings attach to long-term, high-dose, prescription-pattern use; OTC labeling was deliberately not changed for fracture risk.
• For dossier and evidence teams, per-agent PPI figures must be anchored with exposure and duration context. An omeprazole number in a multi-hundred-million-patient-per-year population is not meaningfully comparable across agents within a near-bioequivalent class, and a serious-share percentage in an older chronic-use population is not incidence; quoting raw volumes or shares without exposure and duration context invites a misread.

Sources

• US FDA, openFDA FAERS (Adverse Event Reporting System) extract, export dated 2026-06-08 (20,328,575 total reports). Per-drug, class-union, outcome, AE-family, sex, and trajectory aggregates computed by PharmaDossier from the public FAERS extract. https://open.fda.gov/data/faers/
• US FDA. Drug Safety Communications on proton pump inhibitors — fracture risk (May 25, 2010); hypomagnesemia (March 2, 2011; 74 omeprazole cases identified in FAERS); Clostridium difficile-associated diarrhea (February 8, 2012). Referenced in FDA NDA 0207920 (Rx-to-OTC switch) and NDA 0209400 multidiscipline reviews. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209400Orig1s000CrossR.pdf and https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207920Orig1s000MedR.pdf
• US FDA. NDA 214278 (esomeprazole magnesium delayed-release capsules, Rx-to-OTC) Multidiscipline Review, 2020 — May 14, 2020 recommendation to revise the Rx PPI class renal warning from "acute interstitial nephritis" to "acute tubulointerstitial nephritis" (acute and chronic phases); NISS 392/TSI 1781; summary of PPI class warnings (gastric malignancy, acute interstitial nephritis, CDAD, bone fracture, CLE/SLE, fundic gland polyps, B12 deficiency, hypomagnesemia, clopidogrel and methotrexate interactions). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214278Orig1s000MultidisciplineR.pdf
• Pantoprazole (Protonix) prescribing information, Warnings and Precautions — acute interstitial nephritis; CDAD; bone fracture (high-dose, long-term); cutaneous and systemic lupus erythematosus (majority SCLE, weeks to years after continuous therapy); cyanocobalamin (B12) deficiency with long-term use; hypomagnesemia; fundic gland polyps. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020987s058,022020s021lbl.pdf
• Lansoprazole (Prevacid) prescribing information, Warnings and Precautions — cutaneous and systemic lupus erythematosus; onset days to years; most patients improve with PPI discontinuation in 4–12 weeks. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020406s087s088,021428s034s035lbl.pdf
• Esomeprazole (Nexium) prescribing information, Warnings and Precautions — bone fracture (high-dose, long-term); acute interstitial nephritis; cutaneous lupus erythematosus; hypomagnesemia; B12 deficiency. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021153s052_22101s016_21957s019lbl.pdf
• US FDA. Vonoprazan (Voquezna) Integrated Review, NDA 215151, 2024 — PPI class adverse events of special interest grouped as acid-suppression-related (CDAD, hypomagnesemia, B12 deficiency, fundic gland polyps) and non-acid-suppression-related (severe cutaneous adverse reactions, acute tubulointerstitial nephritis, CLE/SLE). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215151Orig1s000IntegratedR.pdf
• Lazarus B, et al. "Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease." JAMA Internal Medicine 2016;176(2):238–246 — PPI use associated with incident CKD; idiosyncratic interstitial nephritis progressing to chronic disease. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2484291
• Gomm W, et al. "Association of Proton Pump Inhibitors With Risk of Dementia: A Propensity-Matched Analysis." JAMA Neurology 2016;73(4):410–416 — observational PPI–dementia association; North Dakota/Thyrian German study. https://jamanetwork.com/journals/jamaneurology/fullarticle/2491337
• Qiu C, et al. "Proton pump inhibitors and cognitive decline: evidence from UK Biobank and FinnGen." BMC Medicine 2022;20:1–12. https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-022-02516-8
• Northshore/Lehault. "Review of the Long-Term Effects of Proton Pump Inhibitors." — long-term PPI AEs: calcium/magnesium malabsorption, B12 deficiency, CDAD, community-acquired pneumonia, CKD, dementia (Gomm 2016; Lazarus 2016). https://cdn.mdedge.com/files/s3fs-public/0217FP_Lehault.PDF
• US FDA, Drugs@FDA approval records — omeprazole (Prilosec, 1989), lansoprazole (Prevacid, 1995), rabeprazole (AcipHex, 1999), pantoprazole (Protonix, 2000), esomeprazole (Nexium, 2001), dexlansoprazole (Dexilant, 2009). https://www.accessdata.fda.gov/scripts/cder/daf/